Description
Goat Anti-Human Apolipoprotein B-100 Sepharose 4B™ Gel | ABMC-G03
Host Species: | Goat |
Concentration: | ≥ 5 mg/ml |
Source: |
Polyclonal goat antibody human apo B100 coupled with CNBr-activated Sepharose 4B™. |
Preservation: |
75 mM PBS, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, 0.1mM PMSF, pH 7.3. |
Specificity |
Specifically binds to human apo B100. |
Use: |
Affinity purification column. |
Storage: |
2-8ºC store in buffer with 0.5 mM EDTA and 0.02% NaN3, 0.1 mM PMSF. DO NOT FREEZE! |
*Sepharose is a trademark of GE Healthcare Life Sciences, Sweden.
** These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
IMPORTANCE
ApoB exists in human plasma in two isoforms, ApoB-48 (Chen et al., 1987) and Apo B-100 (Wei et al., 1985, Yang et al., 1986a; 1989a,b; 1990; Chen et al., 1986; Yang et al., 1990, Yang and Pownall, 1992). Apo B-100 is the major physiological ligand for the LDL receptor. Apo B-100 is a large monomeric protein, containing 4536 amino acids (m.w. 515 kDa, Yang et al., 1986b).
Apo B-100 is synthesized in the liver and is required for the assembly of VLDL. It is found in LDL and VLDL after the removal of the Apo A, E and C. Apo B-48 is present in chylomicrons and their remnants. It is essential for the intestinal absorption of dietary lipids. Apo B levels correlate with the risk of coronary disease.
The Apo B protein is directly involved in the retention of LDL with the arterial wall (Olofsson and Boren, 2012). Apo B-48 is synthesized in the small intestine. It comprises approximately half of the N-terminal region of ApoB-100 and is the result of posttranscriptional mRNA editing by a stop codon in the intestine not found in the liver.